NCT-10001 fully potentiates α2 and α3 GABAAR subtypes. As a result, it is highly effective in animal models of epilepsy, pain and anxiety. Furthermore, NCT-10001 does not potentiate the α1 or α5 subtypes. Therefore, it should not cause side effects commonly seen with non-selective benzodiazepines such as drowsiness, lethargy, dizziness, and cognitive dysfunction.
In preclinical studies, NCT-10001 was superior or equivalent to diazepam (a commonly prescribed anticonvulsant) in multiple epilepsy models. It has a significantly wider margin of effect vs both motor-impairment and sedation than diazepam. This should translate to an effective treatment that has fewer and less severe side effects than existing therapies. Furthermore, we are uncovering evidence that our compound can treat refractory epilepsy, and unlike many treatments – tolerance to our compound does not develop. We need funding to complete the activities required to begin clinical trials and attract venture capital.
NCT-10001 demonstrates superiority to the first line therapeutic gabapentin in the rat spinal nerve ligation assay. This compound is also highly effective in the Complete Freund’s Adjuvant induced hyperalgesia model, and elicits nearly 100% of the maximum potential effect over 12 days of dosing. Furthermore, NCT-10001 outperforms tramadol (an opioid analgesic) in the formalin-induced allodynia model.